Catalyst Event
Moderna Inc (MRNA) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
8/5/2026, 12:00:00 AM
FDA target action (PDUFA) date for its decision on the approval of Moderna's seasonal influenza vaccine, mRNA-1010, scheduled. High impact expected as a major product approval catalyst.
Korean Translation
미국 식품의약국(FDA), 모더나의 계절성 인플루엔자 백신 mRNA-1010에 대한 승인 결정 목표일(PDUFA) 예정됨. 주요 제품 승인 결정으로 높은 영향이 예상됨.
Related Recent Events
Costco Wholesale Corp (COST) · Earnings Release
Q4 2026 earnings release scheduled. Low importance estimated as it is a routine quarterly update.
9/24/2026, 12:00:00 AM
NetApp Inc (NTAP) · Earnings Release
NetApp is scheduled to announce its financial results for the first quarter of fiscal year 2027 on September 2, 2026, as per the company's investor relations page. Market impact is estimated at 5% based on historical earnings volatility, scheduled.
9/2/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA is scheduled to release its Q2 2027 fiscal year earnings report after the market closes on August 26, 2026, followed by a conference call; high price impact (>10%) is expected based on historical earnings volatility scheduled
8/26/2026, 12:00:00 AM
Snowflake Inc (SNOW) · Earnings Release
Snowflake is expected to announce its financial results for the second quarter of fiscal year 2027 on 2026-08-26, scheduled. Earnings releases for high-growth tech stocks typically result in price moves exceeding 5%.
8/26/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart is scheduled to release its Q2 FY2027 earnings results on August 20, 2026, before the market opens; Medium importance is estimated as earnings reports often lead to price adjustments expected.
8/20/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Target is scheduled to report Q2 2026 earnings on August 19, 2026; analysts forecast EPS of $2.21-$2.26. Medium importance is estimated based on historical earnings volatility exceeding 5% expected.
8/19/2026, 12:00:00 AM